ADVENTRX: Partners

OPPORTUNITIES

OPPORTUNITIES

ADVENTRX Pharmaceuticals actively seeks new partnership opportunities to expand and improve its research, development and commercialization efforts. The Company is committed to creating relationships that are beneficial to both the goals of its partners and goals of the Company. Contact Brian Culley, chief business officer and senior vice president of business development at 858/552-0866 or busdev@adventrx.com to inquire about partnering opportunities.

Biotech Companies
The Company is interested in new collaborations, licenses and acquisitions regarding viable drug candidates for cancer and infectious disease applications, especially those where preclinical testing has demonstrated proof of concept, and there is a desire to expand efforts to human testing.

Partners can benefit from the collective experience of the Company's management team in bringing innovative technology from the development stage to niche pharmaceutical markets.

Pharmaceutical Companies
ADVENTRX Pharmaceuticals appreciates the importance of accelerating time to market for important therapeutic products. The Company will explore opportunities with pharmaceutical companies focused on products for cancer and infectious diseases.

Products available for immediate licensing:
Currently, our efforts and the majority of our resources are focused on advancing our lead emulsion formulation product candidates, ANX-530 and ANX-540, as well as CoFactor. Accordingly, the Company will consider out-licensing the following and other product candidates:

ANX-015, a novel formulation of clarithromycin. An intravenous formulation of clarithromycin is approved to treat mild to moderate bacterial infections (such as community-acquired pneumonia). ANX-015 is intended to reduce injection site reactions associated with intravenous delivery of clarithromycin;
ANX-016, a novel formulation of vancomycin. An intravenous formulation of vancomycin is approved to treat Gram-positive bacterial infections. ANX-016 is intended to reduce injection site reactions associated with intravenous delivery of vancomycin;
ANX-201, a member of a new class of reverse transcriptase inhibitor, that in preclinical studies has shown broad-spectrum antiviral activity against human immunodeficiency virus (HIV), human and avian influenza viruses and herpes simplex viruses (HSV);
ANX-513, a novel formulation of paclitaxel. Taxol, a branded formulation of paclitaxel, is approved to treat breast, ovarian, Kaposi's sarcoma and non-small cell lung cancers. ANX-513 is intended to be non-allergenic and to reduce the need for immunosuppressant premedication associated with administration of Taxol; and
ANX-575, a novel formulation of alpha-tocopheryl succenate, which has been shown in preclinical studies to selectively facilitate cell death in cancer cells.